Inovio Pharmaceuticals to Participate on Panel at 2017 BIO International Convention
June 19 2017 - 8:00AM
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that Dr.
J. Joseph Kim, President & CEO, will participate on a panel,
titled “Platform Technologies: The Key to Responding to Emerging
Infectious Diseases,” at the 2017 BIO International Conference at
the San Diego Convention Center on Wednesday, June 21, 2017, at
1:45pm PT.
New platform technologies based on important
scientific advances are being recognized as the best way to develop
vaccines and therapeutics for emergency situations. This panel will
explore the latest scientific and clinical advances in the
development of such platform technologies, and highlight novel
partnerships and approaches that are leveraging such technologies
to speed up response times to and the ability to potentially
conquer novel pathogens.
Inovio’s DNA-based platform, which is the
foundation of all Inovio products, is unique in its ability to
leverage the body’s naturally existing mechanisms to generate
robust, highly targeted immune responses to prevent and treat
disease – and to do so in the body with a favorable safety profile.
Its SynCon® immunotherapy design technology allows rapid
development of new products to stimulate effective immune responses
against targeted infectious diseases and cancers. Inovio has
demonstrated this rapid and robust capability with its vaccines for
HIV, Ebola, MERS and Zika, where the immune response rates
consistently ranged from 90 to 100% in phase 1 studies. In fact,
Inovio’s Zika vaccine advanced from concept design to the start of
human trials in about six months, establishing this product as
having one of the fastest times for such development. These
results have validated the potential of Inovio’s technology
platform to respond rapidly to global health emergencies.
About Inovio Pharmaceuticals,
Inc.
Inovio is taking immunotherapy to the next level
in the fight against cancer and infectious diseases. We are the
only immunotherapy company that has reported generating T cells in
vivo in high quantity that are fully functional and whose killing
capacity correlates with relevant clinical outcomes with a
favorable safety profile. With an expanding portfolio of immune
therapies, the company is advancing a growing preclinical and
clinical stage product pipeline. Partners and collaborators include
MedImmune, Regeneron Pharmaceuticals, Genentech, GeneOne Life
Science, Plumbline Life Sciences, ApolloBio Corporation, The Wistar
Institute, Laval University, University of Pennsylvania, Drexel
University, DARPA, NIH, HIV Vaccines Trial Network, National Cancer
Institute, and U.S. Military HIV Research Program. For more
information, visit www.inovio.com.
This press release contains certain
forward-looking statements relating to our business. Actual events
or results may differ from the expectations set forth herein as a
result of a number of factors, including the availability and
timing of data from ongoing clinical trials, uncertainties inherent
in the completion of ongoing clinical trials and the
initiation of future clinical trials, whether the results of
earlier clinical trials will be indicative of the results of future
trials, expectations for regulatory approvals, the availability of
funding to support continuing research and studies, the adequacy of
our capital resources, the availability or potential availability
of alternative therapies or treatments for the conditions targeted
by the company or its collaborators, including alternatives that
may be more efficacious or cost effective than any therapy or
treatment that the company and its collaborators hope to develop
and other factors discussed in the “Risk Factors” section of our
Annual Report on Form 10-K for the year ended December 31, 2016,
filed with the U.S. Securities and Exchange Commission (SEC) on
March 15, 2017, our Form 10-Q for the quarter ended March 31, 2017,
filed with the SEC on May 10, 2017, and other filings that Inovio
makes with the SEC from time to time. There can be no assurance
that any product candidate in Inovio's pipeline will be
successfully developed or manufactured, that final results of
clinical trials will be supportive of regulatory approvals required
to market licensed products, or that any of the forward-looking
information provided herein will be proven accurate.
In addition, the forward-looking statements
included in this press release represent Inovio’s views as of the
date hereof. Inovio anticipates that subsequent events and
developments may cause its views to change. However, while Inovio
may elect to update these forward-looking statements at some point
in the future, the company specifically disclaims any obligation to
do so, except as may be required by law. These forward-looking
statements should not be relied upon as representing Inovio’s views
as of any date subsequent to the date of this release.
CONTACTS:
Investors: Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101, bhertel@inovio.com
Media: Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211, jrichardson@inovio.com
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Jul 2023 to Jul 2024